A recent study using the 2016 genome-wide association study (GWAS) identified that vascular mechanisms, but also neuronal and metal ion homeostasis, may play a role in migraine susceptibility.
A recent study using the 2016 genome-wide association study (GWAS) identified that vascular mechanisms, but also neuronal and metal ion homeostasis, may play a role in migraine susceptibility.
Migraine is a disease that is heavily associated with both genetic and environmental factors. Although there has been considerable progress in understanding its underlying pathology, much remains to be discovered. One area of research that investigators are examining comprises the genetic variants that may be associated with migraines. In a recent study, investigators used the 2016 GWAS to identify DNA variants that may be linked to migraines.
Investigators have conducted several GWAS in patients with migraines, with or without aura. In 2016, a meta-analysis on genomic data on previous cohorts was performed to yield a larger population sample. The data consisted of 59,674 cases and identified 44 cases of single nucleotide polymorphisms.
Based on the results of the 2016 GWAS, investigators found a vast amount of enrichment in the genes associated with the vascular system as identifiable risk factors for migraine. Tissue expression enrichment analysis was also performed and identified that arterial and gastrointestinal tissues were significantly enriched for migraine-associated genes. Four of the genes significantly enriched in vascular tissues were MEF2D, YAP1, LRP1, and JAG1.
The findings of the 2016 GWAS suggest that vascular dysfunction plays a large role in migraine susceptibility, but the investigators do not rule out neurologic dysfunction as another source of origin for migraines. Of the genes that were identified, at least 5 genes had neuronal function (PRDM16, MEF2D, FHL5, ASTN2, LRP1). Metal ion homeostasis was another contributor of migraine susceptibility, as 11 genes were identified (PRDM16, TGFBR2, REST, FHL5, NRP1, MMPED2, LRP1, ZCCHC14, RNF213, JAG1, SLC24A3). Although ion channel activity and pain signaling emerged as prominent signals of familial hemiplegic migraine, they did not appear so in this study.
The use of GWAS has been paramount in identifying various genomes that present as risk factors for migraines. Larger GWAS should be conducted in the future to identify additional risk factors and help develop more personalized treatment options for patients with migraine.
Reference:
Van der Maagdenberg, Nyholt DR, Anttila V. Novel hypotheses emerging from GWAS in migraine? J Headache Pain. 2019;20(1):5. doi: 10.1186/s10194-018-0956-x.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen